Zenas BioPharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZBIO Nasdaq 2836 zenasbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zenas BioPharma, Inc.

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD - May 28th, 2026 5:05 am
Insiders Buy the Dip in These 2 Crushed Stocks With Strong Buy Ratings - May 21st, 2026 11:58 am
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress - May 19th, 2026 5:05 am
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 18th, 2026 2:15 pm
Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss - May 13th, 2026 11:28 am
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor - May 13th, 2026 4:50 am
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 13th, 2026 4:00 am
IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi Leading - May 7th, 2026 5:34 am
Insiders Are Scooping Up These 2 ‘Strong Buy’ Stocks - Apr 8th, 2026 4:01 am
Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution Risk - Mar 28th, 2026 11:05 pm
Sector Update: Health Care Stocks Softer Late Afternoon - Mar 27th, 2026 1:52 pm
Sector Update: Health Care Stocks Retreat Friday Afternoon - Mar 27th, 2026 11:47 am
Wall Street Set to Open Lower in Friday Trading; Investors Not Assuaged by US Deadline Extension for Iran to Open Strait of Hormuz - Mar 27th, 2026 7:17 am
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million - Mar 26th, 2026 10:12 pm
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock - Mar 26th, 2026 2:01 pm
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch - Mar 21st, 2026 12:23 pm
Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares - Mar 17th, 2026 2:16 am
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Mar 16th, 2026 5:00 am
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight - Mar 10th, 2026 3:31 pm
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory - Feb 28th, 2026 8:56 am